A Pilot study to estimate the efficacy of aroma therapy on insomnia in cancer patients
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0001394
- Lead Sponsor
- Comprehensive and Integrative Medical Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 13
1) History of histologically or cytologically proven cancer.
2) The Eastern Cooperative Oncology Group performance scale: 0-2
3) Patients who had received surgery or radiation therapy or chemotherapy more than 1 month ago.
4) Patients who have experienced insomnia more than 3 months and the ISI (Insomnia Severity Index) score is more than 15.
5) Patients who are able to complete questionnaires.
6) Patients who voluntarily agree to participate and sign the consent form themselves or the form is signed by their guardian
7) Patients for whom follow-up observations are possible throughout the study period.
1) Liver dysfunction: AST, ALT is more than 1.5 times compared with a normal standard.
2) Kidney dysfunction: Creatine is more than 1.5 times compared with a normal standard.
3) Heart disease or uncontrolled hypertension(more than 160/100 mmHg)
4) Patients who are not able to take inhalation.
5) Pregnant, breast-feeding, or woman of childbearing potential not using adequate contraception
6) Patients who are not suitable for this study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI)
- Secondary Outcome Measures
Name Time Method Sleep diary, HRV (Heart Rate Variability), Functional Assessment Cancer Therapy-General (FACT-G), State-Trait Anxiety Inventory (STAI)